ArticleThe oncologist2017
In-Hospital Outcomes of Tumor Lysis Syndrome: A Population-Based Study Using the National Inpatient Sample.
Article in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Tumor Lysis Syndrome in Colorectal Cancer-A Systematic Review of Literature.Journal of gastrointestinal cancer · 2026Pooled it
- Just the facts: tumour lysis syndrome.CJEM · 2026Article
- Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost-effectiveness analysis.British journal of haematology · 2026Article
- Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization - a case report.Biochemia medica · 2026Article
- Tumor Lysis Syndrome in Lung Cancer Patients: A Review of the Literature.Asian Pacific journal of cancer prevention : APJCP · 2026Review
- Spontaneous Tumor Lysis Syndrome as the Initial Presentation of Chronic Lymphocytic Leukemia: A Case Report.Clinical medicine insights. Case reports · 2026Article
- An uncommon encounter with tumor lysis syndrome in colorectal cancer.German medical science : GMS e-journal · 2026Article
- Management of acute kidney injury in tumor lysis syndrome: a narrative review.Internal and emergency medicine · 2025Review
- Article
- Tumour lysis syndrome.Nature reviews. Disease primers · 2024Review
- Prediction of tumor lysis syndrome in childhood acute lymphoblastic leukemia based on machine learning models: a retrospective study.Frontiers in oncology · 2024Article
- Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.Therapeutic advances in drug safety · 2024Article
- Independent predictors of mortality and 5-year trends in mortality and resource utilization in hospitalized patients with diffuse large B cell lymphoma.Proceedings (Baylor University. Medical Center) · 2024Article
- Article
- Tumour lysis syndrome.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Article
- Acute kidney injury following induction of chemotherapy: Diagnosis and management in critical care.Journal of the Intensive Care Society · 2023Article
- Benefit of continuous kidney replacement therapy for managing tumor lysis syndrome in children with hematologic malignancies.Frontiers in oncology · 2023Article
- Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases.Cureus · 2022Review
- Management of acute kidney injury in gastrointestinal tumor: An overview.World journal of clinical cases · 2021Review
Corrections and comments
- Commented on by
- Commented on byIn Reply.2018
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiology and outcomes of tumor lysis syndrome (TLS) are understudied. We used the National Inpatient Sample (NIS), a nationally representative weighted sample of all U.S. hospital discharges, to study outcomes and predictors of mortality in hospitalized patients with TLS. The NIS was queried for patients with a discharge diagnosis of TLS (ICD-9 code 277.88) from 2010-2013. Baseline characteristics and outcomes were analyzed. A multivariable logistic regression analysis was performed to identify predictors of mortality. From 2010-2013, 28,370 patients were discharged with a diagnosis of TLS. The most common malignancies were non-Hodgkin lymphoma (30%), solid tumors (20%), acute myeloid leukemia (19%), and acute lymphocytic leukemia (13%). Overall in-hospital mortality was 21%. The median length of stay was 10 days (IQR 5-22). Sixty-nine percent of patients experienced a severe complication, including sepsis (22%, 95% confidence interval [CI] 21-23), dialysis (15%, 95% CI 14-16), acute respiratory failure (23%, 95% CI 22-24), mechanical ventilation (16%, 95% CI 15-17), gastrointestinal hemorrhage (6%, 95% CI 5-7), cerebral hemorrhage (2%, 95% CI 2-3), seizures (1%, 95% CI 0.6-1), and cardiac arrest (2%, 95% CI 2-3). Predictors of mortality were derived from a multivariable logistic regression and included age, Elixhauser comorbidity score, insurance status, teaching versus nonteaching hospital, and cancer type. Predictors of increased length of stay included age, race, teaching versus nonteaching hospital, and cancer type. In the U.S., many patients with TLS develop life-threatening complications and a quarter die during hospitalization. As more cancer treatments become available, strategies to improve the supportive care of patients with TLS should be a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.